Project Grant R21AI203157
Award Date 8/10/26
Completion Date 7/31/28
Dollars Obligated $199K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Research Foundation For The State University Of New York $799,743 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel dual-acting therapeutics against multidrug-resistant and hypervirulent Klebsiella pneumoniae strains. The project targets the development of first-in-class, dual-acting anti-virulence antibiotics that address a critical gap in current treatment...
- The National Institute of Allergy and Infectious Diseases awarded The Broad Institute, Inc. $480,650 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a genome-wide association study identifying genetic determinants of carbapenem resistance in Klebsiella pneumoniae. The project addresses knowledge gaps in understanding resistance mechanisms in carbapenem-resistant K. pneumoniae strains. The recipient will perform a reference-free GWAS using...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $427,625 Project Grant to the University of North Carolina at Chapel Hill under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period July 1, 2025 through June 30, 2027. The grant funds research investigating the role of fimbriae—surface-expressed protein appendages on bacterial cells—in hypervirulent Klebsiella pneumoniae (HVKP) mediated liver abscess formation....
- The National Institute of Allergy and Infectious Diseases awarded Virtici LLC $306,500 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a first-in-class, orally administered probiotic therapy for treatment and prevention of Klebsiella pneumoniae gastrointestinal colonization, transmission, and infection. The award is a Project Grant with assistance type classification. K. pneumoniae causes pneumonia, urinary tract infections, bloodstream...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $412,942 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how host-derived environmental signals in the gastrointestinal tract regulate hypervirulent Klebsiella pneumoniae virulence gene expression and capsule production during intestinal colonization and systemic dissemination. The research employs RNA sequencing and genetic approaches to...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $427,625 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025 through July 31, 2027. This award supports research investigating antibiotic treatment failure in hypervirulent Klebsiella pneumoniae (HVKP) liver abscesses. The research project will deliver scientific outputs examining...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $726,966 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop maternal vaccines against Klebsiella pneumoniae neonatal sepsis. The work performs at Washington University's Office of Sponsored Research Services in St. Louis, Missouri, through March 31, 2031. The project interrogates immune responses to maternal bioconjugate vaccines targeting K. pneumoniae's...
- The National Institute of Allergy and Infectious Diseases awarded Wake Forest University Health Sciences $149,190 on December 30, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate age-associated changes in B cell and antibody effector responses to Streptococcus pneumoniae. The project uses an aged mouse model to identify mechanisms underlying vaccine-induced protection against pneumonia in elderly individuals, circumventing confounding factors...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $161,244 on April 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct experimental evolution assays elucidating evolutionary trajectories to antibiotic resistance in Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli, and how the immune system modifies these trajectories. The research uses in vivo adaptive laboratory evolution experiments in Galleria...
- The National Institute of Allergy and Infectious Diseases awarded $741,051 to the University of North Carolina at Chapel Hill on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate antibiotic tolerance as a driver of enterobacterales persistence in hematopoietic stem cell transplantation (HCT) patients. The project examines why enterobacterales bacteria persist in the gut despite antibiotic susceptibility and how tolerance—the ability to...